Display options
Cite
Mombeini T, Zahedpoure-Anaraki MR, Dehpour AR. Effects of Sodium Cromoglycate on Iranian Asthmatic Subjects Without Exposure to any Bronchoconstrictor agent. Iran J Pharm Res. 2012;11(2):549-57
Mombeini, T., Zahedpoure-Anaraki, M. R., & Dehpour, A. R. (2012). Effects of Sodium Cromoglycate on Iranian Asthmatic Subjects Without Exposure to any Bronchoconstrictor agent. Iranian journal of pharmaceutical research : IJPR, 11(2), 549-57.
Mombeini, Tajmah, et al. "Effects of Sodium Cromoglycate on Iranian Asthmatic Subjects Without Exposure to any Bronchoconstrictor agent." Iranian journal of pharmaceutical research : IJPR vol. 11,2 (2012): 549-57.
Mombeini T, Zahedpoure-Anaraki MR, Dehpour AR. Effects of Sodium Cromoglycate on Iranian Asthmatic Subjects Without Exposure to any Bronchoconstrictor agent. Iran J Pharm Res. 2012;11(2):549-57. PMID: 24250478; PMCID: PMC3832161.
Copy Download .nbib Format: NLM
Share it on

Iran J Pharm Res. 2012;11(2):549-57.

Effects of Sodium Cromoglycate on Iranian Asthmatic Subjects Without Exposure to any Bronchoconstrictor agent.

Iranian journal of pharmaceutical research : IJPR

Tajmah Mombeini, Mohammad Reza Zahedpoure-Anaraki, Ahmad Reza Dehpour

Affiliations

  1. Department of Pharmacology, School of Medicine, Shahed University, Tehran, Iran. ; Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ; Department of Pharmacology, School of Medicine, Ahwaz -Jondishapour University of Medical Sciences (AJUMS ), Ahwaz, Iran.

PMID: 24250478 PMCID: PMC3832161

Abstract

Cromolyn sodium, a mast cell stabilizing agent, provides an immediate protective effect against the exercise-induced bronchoconstriction while being used before the exercise. However, cromolyn is ineffective in reversing asthmatic bronchospasm; it is used as a maintenance therapy and has a prophylactic role in chronic asthma. The purpose of this study was to determine the extent of change in baseline lung function tests following a single dose of cromolyn sodium in adult asthmatics. Forty volunteers (33 women and 7 men) with moderate to severe persistent asthma were randomly assigned to receive 20 mg cromolyn, 40 mg cromolyn or cromolyn-placebo. The percent of improvement in lung function parameters was compared among the groups, during 1 h of inhalation. Low dose of cromolyn induced more improvement in most lung function parameters such as forced expiratory flow volume in one second, forced vital capacity and peak expiratory flow compared with other groups. After 15 min, the improvement percentage of baseline forced expiratory flow volume in one second was 3.35 ± 1.5, for sodium cromoglycate-20 mg group compared with 0.98 ± 1.43 and - 0.68 ± 1.2 for sodium cromoglycate-placebo and sodium cromoglycate-40 mg, groups respectively. However, the differences between means were not significant. Furthermore, based on the definition of American Thoracic Society (ATS) for a "significant post-bronchodilator response" developed in a few patients 15 min after the inhalation of 20 mg cromolyn sodium. It is suggested that probably the inhalation of 20 mg of cromolyn sodium could immediately improve the lung function in few adults with asthma.

Keywords: Adults; Bronchial asthma; Cromolyn sodium; Forced expiratory flow volume in one second; Lung function tests

References

  1. Ann Allergy Asthma Immunol. 2001 May;86(5):537-44 - PubMed
  2. Clin Allergy. 1984 Jan;14(1):87-91 - PubMed
  3. Cochrane Database Syst Rev. 2003;(3):CD002173 - PubMed
  4. J Asthma. 2010 May;47(4):429-33 - PubMed
  5. Chest. 1990 Jan;97(1):39-45 - PubMed
  6. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003558 - PubMed
  7. Chest. 1994 Mar;105(3):673-80 - PubMed
  8. Thorax. 2002 Aug;57(8):751-2 - PubMed
  9. Cochrane Database Syst Rev. 2003;(4):CD002307 - PubMed
  10. Allergy. 1996 Dec;51(12):870-5 - PubMed
  11. Arzneimittelforschung. 2008;58(6):303-9 - PubMed
  12. Arzneimittelforschung. 1984;34(9):1002-4 - PubMed
  13. Am Rev Respir Dis. 1991 Nov;144(5):1202-18 - PubMed
  14. Am J Respir Crit Care Med. 1994 Feb;149(2 Pt 2):S9-18; discussion S19-20 - PubMed
  15. Pediatr Allergy Immunol. 2002 Jun;13(3):209-16 - PubMed
  16. Thorax. 1985 Jan;40(1):41-4 - PubMed
  17. Treat Respir Med. 2004;3(6):365-79 - PubMed
  18. Lung. 2006 Mar-Apr;184(2):63-72 - PubMed
  19. Ann Allergy Asthma Immunol. 1998 Jun;80(6):494-8 - PubMed
  20. Eur Respir J. 1995 Apr;8(4):600-4 - PubMed
  21. Eur Respir J. 1998 Jul;12(1):50-6 - PubMed
  22. Respir Med. 2006 Mar;100(3):420-33 - PubMed
  23. Biochem Pharmacol. 2009 Jun 15;77(12):1814-26 - PubMed
  24. J Pharmacol Exp Ther. 1987 Jun;241(3):1028-32 - PubMed

Publication Types